/ /

ModernMedicine Resource Center More Topics

Hepatology Resource Center

Triple directing-acting combination treats decompensated liver diseaseA combination of three drugs successfully treats HCV-infected patients with advanced liver disease.
Liver transplant recipients with HCV fare well under drug comboHepatitis C virus infection in liver transplant recipients can be treated with ledipasvir and sofosbuvir without ribavirin.
HBV reactivation with direct acting antivirals for HCV is highly manageableNew study indicates early recognition of HBV-HCV co-infection can lead to prompt treatment of HBV reactivation.
Study: 12 weeks therapy combination cures virtually all HCV patientsA shorter, triple DAA therapy combination is not superior to 12 weeks of sofosbuvir plus velpatasvir in chronic HCV patients, according to researchers.
DAAs dramatically increase HCV cure rates among veteransThe introduction of direct-acting antiviral agents has transformed hepatitis C care among veterans.
Multiple DAAs provide quality care for HCV patientsMultiple oral direct-acting antiviral agents show great promise in treating the vast majority of hepatitis C patients.
Real-world DAA therapy shows gains in community settingPhysicians have a “good, effective, safe therapy available” for hepatitis C virus genotype 6 patients, says researcher.
Study: DAA all-oral combination successful in treating hepatitis CEarly data shows promise in “real-world” effectiveness.
DAAs do not increase risk of hepatic decompensation in HCV patientsResearchers say theirs is first national study with a large population to examine possible link.
DAA therapy effective in advanced liver disease in real-world studyAll-oral sofosbuvir-based therapy proves a significant advance for hepatitis C virus patients.